MedTrace Logo

Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study

NCT01915238 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2017-08-30

No results posted yet for this study

Summary

Background:

\- The Age-Related Eye Disease 2 Study (AREDS2) looked at two eye diseases. These were age-related macular degeneration (AMD) and cataracts. Participants in that study took supplement pills and some participants had additional pictures taken of their eyes. That study is now over. Researchers want to do a follow-up study after participants finish taking the pills, to see if they cause long-term effects on AMD. This study will be combined with follow-up visits of the AREDS2 study if possible.

Objectives:

\- To learn more about the effect of oral supplements on AMD.

Eligibility:

\- People who completed the AREDS2 study.

Design:

* Participants will have up to 2 study visits over 6 18 months.
* Each visit will last up to 5 hours. The visits will be combined with annual follow-up visits in the AREDS2 study if possible.
* At each visit, participants will undergo an eye exam and photography.
* The eye exam includes testing sight, measuring eye pressure, and checking eye movements. To examine the inside of the eye, the pupil will be dilated with eye drops.
* Photographs of the inside of the eye may be taken during the eye exam and while the eyes are dilated.
* A contact lens may be placed on the eye briefly to look at the retina at the back of the eye.

Conditions

  • AMD
  • Age- Related Macular Degeneration

Sponsors & Collaborators

  • National Eye Institute (NEI)

    lead NIH

Principal Investigators

  • Wai T Wong, M.D. · National Eye Institute (NEI)

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-16
Primary Completion
2014-06-20
Completion
2014-06-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915238 on ClinicalTrials.gov